CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

The FDA canceled a vaccine advisory committee meeting to discuss influenza virus strains that should be included in shots for ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Most immediately, Moderna has received Prescription Drug User Fee Act (PDUFA) goal dates for two vaccines in 2025. The FDA is set to provide an approval decision on the company’s next-generation ...

Pharmaceutical giant Moderna (MRNA) released mixed fourth quarter ... GLP-1s and the availability of those cheaper compounded versions of these drugs to folks and what that might look like under ...

In September, the company announced plans to cut its R&D costs and focus on winning approval for drugs in later stage trials. Moderna reported a wider loss than expected for the fourth quarter on ...

U.S. involvement in WHO flu meetings, the UK's approval of Moderna's RSV vaccine, efforts against a measles outbreak in Texas ...